Annual report
2269.TEDINET S100PUW9
Period2021-04-01 → 2022-03-31
Filed2022-12-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100OJZO. Amended by S100PV0B (2022-12-22).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.01T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥1.19T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥1.25T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.25T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.24T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥92.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥106.1bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥94.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥110.2bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥103.3bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥99.7bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥95.9bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥128.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥103.2bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥87.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥65.7bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥67.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥61.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥61.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥92.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥70.1bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥1.12T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.07T | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥998.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥925.2bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥404.4bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥407.6bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥713.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥659.4bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥597.6bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥560.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥495.2bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥67.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥40.3bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥64.9bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.0bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥24.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥26.9bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥127.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥123.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥114.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥112.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥108.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥93.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥70.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥100.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥77.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥28.3bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥30.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14.0bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥40.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥607.24 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥452.52 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥464.08 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥426.61 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥422.15 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,781.52 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,282.8 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,879.18 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,635.79 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,360.7 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 60.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.2% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.5% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 13.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.1% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 17,336 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 17,832 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 17,571 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 17,608 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 16,296 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥34.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.5bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥23.3bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥21.6bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥19.6bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥30.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥22.3bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥31.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥22.9bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥21.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥31.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥31.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.4bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.8bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥18.0bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥391.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥386.1bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥378.8bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥385.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥386.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥145.4bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥120.0bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥246.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥266.1bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥262.2bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥265.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥266.3bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥11.5bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥220.25 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.07 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥145.69 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.71 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥124 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥170 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥140 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,747.21 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,834.08 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,807.6 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,833.11 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,836.25 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.9% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.9% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.2% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.9% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.8% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 148,369,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 152,683,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 85 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 35 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥191m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥223m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥969m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥969m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥7.2bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Foodreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥79.9bn |
| Foodreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥40.6bn |
| Foodreportable segment | employees | at 2022-03-31 | 10464 pure |
| Foodreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥826.1bn |
| Foodreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥825.5bn |
| Foodreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥629m |
| Foodreportable segment | segment assets | at 2022-03-31 | ¥796.7bn |
| Foodreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Pharmaceuticalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥15.4bn |
| Pharmaceuticalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥9.3bn |
| Pharmaceuticalsreportable segment | employees | at 2022-03-31 | 6783 pure |
| Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥188.0bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥187.6bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥340m |
| Pharmaceuticalsreportable segment | segment assets | at 2022-03-31 | ¥327.9bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥18.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥95.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥49.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥1.01T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥1.01T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥969m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.12T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥94.6bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥179m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥215m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥25.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥507m |
| Foodreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥55.9bn |
| Foodreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥39.3bn |
| Foodreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥999.7bn |
| Foodreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥999.0bn |
| Foodreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥684m |
| Foodreportable segment | segment assets | at 2021-03-31 | ¥755.2bn |
| Foodreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥87.5bn |
| Pharmaceuticalsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥12.7bn |
| Pharmaceuticalsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥8.9bn |
| Pharmaceuticalsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥193.7bn |
| Pharmaceuticalsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥192.8bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥888m |
| Pharmaceuticalsreportable segment | segment assets | at 2021-03-31 | ¥286.4bn |
| Pharmaceuticalsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥19.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥68.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥48.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥1.04T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥106.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,873
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.888 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.999 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.874 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.831 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.794 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.443 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 10464 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 5177 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 6783 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 2661 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 89 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 26 | |
| Number of employees | CurrentYearInstant | 17336 | |
| Average number of temporary workers | CurrentYearInstant | 7864 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 85 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 44.9 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 20.6 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 10150000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 85 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 13 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 85 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 13 | |
| Research and development expenses research and development activities | CurrentYearDuration | 33441000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 13305000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 19243000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 93594000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000FoodReportableSegmentsMember | 78461000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E21902-000PharmaceuticalsReportableSegmentsMember | 14971000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 148369500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 148369500 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 148369500 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 148369500 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 143 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 780 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 659 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 63 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 88765 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 90453 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 578956 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 31857 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |